Payment overview · 2025
General Payments
$528.78
31 reported records · 12 companies
Healthcare provider profile · identity verified
Alejandro N Martinez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CAPE CORAL, FL · NPI 1659352953
Verified facts
What the public records show
CMS Open Payments records show Alejandro N Martinez, M.D. received $528.78 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $214.11 | 40.5% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $73.30 | 13.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.98 | 9.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.73 | 6.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.60 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.02 | 4.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.64 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.66 | 3.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.04 | 3.2% | 1 | 2025 |
| Vapotherm Inc | Unresolved — no canonical attribution shown | $14.96 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.04 | 2.7% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $12.70 | 2.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $528.78 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $147.25 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $100.29 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $73.30 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.86 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.98 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.60 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| VAPOTHERM Normalized: vapotherm |
Device | Vapotherm Inc | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $12.70 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 55 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1043 | 286 |
| Amlodipine Besylate | Amlodipine Besylate | 915 | 261 |
| Levothyroxine Sodium | Levothyroxine Sodium | 785 | 203 |
| Lisinopril | Lisinopril | 693 | 178 |
| Losartan Potassium | Losartan Potassium | 610 | 161 |
| Simvastatin | Simvastatin | 573 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 505 | 142 |
| Alprazolam | Alprazolam | 435 | 94 |
| Metformin Hcl | Metformin Hcl | 406 | 114 |
| Omeprazole | Omeprazole | 360 | 110 |
| Gabapentin | Gabapentin | 332 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 284 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 93 |
| Zolpidem Tartrate | Zolpidem Tartrate | 252 | 53 |
| Meloxicam | Meloxicam | 235 | 66 |
| Lovastatin | Lovastatin | 234 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 73 |
| Montelukast Sodium | Montelukast Sodium | 224 | 59 |
| Eliquis | Apixaban | 214 | 45 |
| Trazodone Hcl | Trazodone Hcl | 195 | 43 |
| Furosemide | Furosemide | 192 | 58 |
| Celecoxib | Celecoxib | 191 | 57 |
| Famotidine | Famotidine | 170 | 49 |
| Methylprednisolone | Methylprednisolone | 167 | 124 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 41 |
| Mirtazapine | Mirtazapine | 143 | 41 |
| Atenolol | Atenolol | 142 | 38 |
| Ezetimibe | Ezetimibe | 141 | 35 |
| Torsemide | Torsemide | 141 | 44 |
| Tramadol Hcl | Tramadol Hcl | 141 | 44 |
| Januvia | Sitagliptin Phosphate | 140 | 25 |
| Allopurinol | Allopurinol | 135 | 39 |
| Jardiance | Empagliflozin | 131 | 30 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 128 | 34 |
| Sertraline Hcl | Sertraline Hcl | 122 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 32 |
| Potassium Chloride | Potassium Chloride | 114 | 27 |
| Prednisone | Prednisone | 114 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 111 | 27 |
| Baclofen | Baclofen | 109 | 61 |
| Azithromycin | Azithromycin | 108 | 84 |
| Glimepiride | Glimepiride | 103 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 28 |
| Synthroid | Levothyroxine Sodium | 99 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 28 |
| Lorazepam | Lorazepam | 94 | 13 |
| Buspirone Hcl | Buspirone Hcl | 92 | 28 |
| Ibuprofen | Ibuprofen | 91 | 28 |
| Carvedilol | Carvedilol | 89 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 26 |
| Benazepril Hcl | Benazepril Hcl | 88 | 26 |
| Clonidine Hcl | Clonidine Hcl | 88 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 21 |
| Spironolactone | Spironolactone | 78 | 28 |
| Bupropion Xl | Bupropion Hcl | 77 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 16 |
| Alendronate Sodium | Alendronate Sodium | 75 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 18 |
| Ozempic | Semaglutide | 73 | 16 |
| Clonazepam | Clonazepam | 70 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 18 |
| Ketoconazole | Ketoconazole | 60 | 20 |
| Fenofibrate | Fenofibrate | 59 | 19 |
| Mounjaro | Tirzepatide | 58 | 12 |
| Nifedipine Er | Nifedipine | 57 | 16 |
| Glipizide | Glipizide | 55 | 13 |
| Rybelsus | Semaglutide | 55 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 11 |
| Risperidone | Risperidone | 53 | suppressed |
| Temazepam | Temazepam | 50 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 32 |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Enalapril Maleate | Enalapril Maleate | 47 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 18 |
| Valacyclovir | Valacyclovir Hcl | 46 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 12 |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 25 |
| Meclizine Hcl | Meclizine Hcl | 39 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 11 |
| Finasteride | Finasteride | 37 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 33 |
| Promethazine Hcl | Promethazine Hcl | 34 | 27 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 11 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 13 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $528.78 · 31 records | Novo Nordisk Inc | ABRYSVO, Barostim Neo System, COMIRNATY, Dexcom G6 Transmitter, EVENITY, MOUNJARO, ONPATTRO, Ozempic, PREVNAR 20, Rybelsus, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, VAPOTHERM, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error